Durable Responses and Survival in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients Receiving the Allogeneic Leukemia-derived Dendritic Cell Vaccine DCP-001

LLG Janssen; TM Westers; J Rovers; PJM Valk; J Cloos; TD de Gruijl; AA van de Loosdrecht

doi:10.1097/HS9.0000000000000968

Durable Responses and Survival in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients Receiving the Allogeneic Leukemia-derived Dendritic Cell Vaccine DCP-001

LLG Janssen
, TM Westers
, J Rovers
, PJM Valk
, J Cloos
, TD de Gruijl
, AA van de Loosdrecht

Hematology

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

4 Citations (Scopus)

121 Downloads (Pure)

Original language	English
Pages (from-to)	E968
Journal	HemaSphere
Volume	7
Issue number	11
DOIs	https://doi.org/10.1097/HS9.0000000000000968
Publication status	Published - 2 Nov 2023

Bibliographical note

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1097/HS9.0000000000000968Licence: CC BY-NC-ND

durable_responses_and_survival_in_high_risk.11Final published version, 405 KBLicence: CC BY-NC-ND

Cite this

@article{06f9f512529b4cf98263db5348f36642,

title = "Durable Responses and Survival in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients Receiving the Allogeneic Leukemia-derived Dendritic Cell Vaccine DCP-001",

author = "LLG Janssen and TM Westers and J Rovers and PJM Valk and J Cloos and \{de Gruijl\}, TD and \{van de Loosdrecht\}, AA",

note = "Copyright {\textcopyright} 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. ",

year = "2023",

month = nov,

day = "2",

doi = "10.1097/HS9.0000000000000968",

language = "English",

volume = "7",

pages = "E968",

journal = "HemaSphere",

issn = "2572-9241",

publisher = "John Wiley \& Sons Inc.",

number = "11",

}

Durable Responses and Survival in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients Receiving the Allogeneic Leukemia-derived Dendritic Cell Vaccine DCP-001. / Janssen, LLG; Westers, TM; Rovers, J et al.
In: HemaSphere, Vol. 7, No. 11, 02.11.2023, p. E968.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Durable Responses and Survival in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients Receiving the Allogeneic Leukemia-derived Dendritic Cell Vaccine DCP-001

AU - Janssen, LLG

AU - Westers, TM

AU - Rovers, J

AU - Valk, PJM

AU - Cloos, J

AU - de Gruijl, TD

AU - van de Loosdrecht, AA

PY - 2023/11/2

Y1 - 2023/11/2

UR - https://www.scopus.com/pages/publications/85180979685

U2 - 10.1097/HS9.0000000000000968

DO - 10.1097/HS9.0000000000000968

M3 - Comment/Letter to the editor

C2 - 37928626

SN - 2572-9241

VL - 7

SP - E968

JO - HemaSphere

JF - HemaSphere

IS - 11

ER -

Durable Responses and Survival in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients Receiving the Allogeneic Leukemia-derived Dendritic Cell Vaccine DCP-001

Bibliographical note

UN SDGs

Access to Document

Other files and links

Cite this